InMode Ltd. (INMD) Stock Price & Analysis
InMode Ltd. (INMD) closed at USD 13.37 on Wednesday, October 28, 2026, down 1.55% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.58; the Oct 28, 2026 session ranged USD 13.32–13.62 on volume of 536,105 shares. Market capitalization is $769.37M, with a 52-week range of USD 12.72–16.67 (NMS). Source: Nexqual, retrieved October 29, 2026 at 02:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/INMD.md
Key facts (INMD)
- 1 of 80 tracked superinvestors hold INMD (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (5 analysts), mean target USD 16.17 (range 15–17).
- Total return with dividends: 1Y -10.4% vs S&P 500 +13.6%; 5Y -85.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-11, EPS estimate USD 0.32, revenue estimate $90.8M.
Superinvestors (SEC 13F-HR, Q2 2026) (INMD)
1 of 80 tracked investors hold INMD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Sarah Ketterer | Causeway Capital Management | <0.01% | $266K | Reduced -74.7% |
Analysts (INMD)
Consensus Hold (mean 3.00 on a 1–5 scale), 5 analysts; mean target USD 16.17 (low 15, high 17).
Total return (dividends reinvested) (INMD)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -10.4% | -85.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -10.4% | -32.4% |
| Volatility (annualized) | 29.7% | 46.3% |
| Max drawdown | -23.2% (Feb 2026→Mar 2026) | -86.0% (Oct 2021→Mar 2026) |
INMD major shareholder filing: Schedule 13D/A, Oct 21, 2026
Moshe Mizrahy filed a Schedule 13D/A with the SEC on Oct 21, 2026, reporting up to 7.90% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
Item 4 of the Schedule 13D is amended by adding the following: On September 15, 2026, M.N. Business Strategy the Company announced that the offer expired at 11:59 p.m., New York time, and was not further extended. (see Exhibit 99.2).
Source: SEC EDGAR, Schedule 13D/A filed Oct 21, 2026. Quoted word for word; Nexqual adds no interpretation.
INMD earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.35 | $0.33 | Beat +6.1% | — |
| — | Quarter ended Mar 31, 2026 | $0.25 | $0.30 | Miss −16.7% | — |
| — | Quarter ended Dec 31, 2025 | $0.46 | $0.42 | Beat +9.5% | — |
| — | Quarter ended Sep 30, 2025 | $0.38 | $0.35 | Beat +8.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
INMD recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 26, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 26, 2026 |
| Oct 21, 2026 | Schedule 13D/A | Moshe Mizrahy: 7.9% of shares, 5%+ holder that may seek to influence the company (amended) “Item 4 of the Schedule 13D is amended by adding the following: On September 15, 2026, M.N. Business Strategy the Company announced that the offer expired at 11:59 p.m., New York time, and was not further extended. (see Exhibit…” |
| Sep 16, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 16, 2026 |
| Aug 11, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 11, 2026 |
| Aug 5, 2026 | Schedule 13D/A | Moshe Mizrahy: 7.9% of shares, 5%+ holder that may seek to influence the company (amended) “Item 4 of the Schedule 13D is amended by adding the following: On July 8, 2026, M.N. Business Strategy delivered a letter to the issuer extending the expiration date for the proposal to September, 15, 2026 (see Exhibit…” |
| Aug 5, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 5, 2026 |
| Aug 3, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 3, 2026 |
| Jul 20, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 20, 2026 |
| Jul 13, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 13, 2026 |
| Jul 10, 2026 | 6-K | Current report (foreign issuer) · period ended Jul 10, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
INMD suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Medimor | “main manufacturing subcontractors (Flex and Medimor) do not have minimum purchase requirements and allow us to purchase end products on” |
| Competitor | AbbVie (ABBV) | “Our products compete against products offered by public companies, including AbbVie” |
Quoted from the company's 20-F filed Feb 10, 2026.
Companies that name INMD in their SEC reports
| Relationship to INMD | Company | Filing | Sentence |
|---|---|---|---|
| partner | SBC Medical Group Holdings Inc (SBC) | 10-K Mar 27, 2026 | “Braun SE, Cynosure Lutronic, Evolus, Inc., Galderma S.A., Genesis Biosystems, Inc., Inmode Ltd., IRIDEX Corporation, Lumenis Be Ltd., Sinclair Pharma Limited, Stryker Corporation, and Surgery Partners.” |
INMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.32 | $0.34 | -4.7% | $90.8M | 5 |
| Next quarter (ends Dec 2026) | $0.38 | $0.42 | -9.0% | $101.1M | 5 |
| Current fiscal year (ends Dec 2026) | $1.30 | $1.32 | -2.0% | $370.3M | 5 |
| Next fiscal year (ends Dec 2027) | $1.37 | $1.45 | -5.2% | $378.8M | 5 |
INMD options: expected move
Options price a move of about ±16.0% (±$2.14) by Nov 20, 2026, which includes earnings on Nov 11, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 39.5% | ±16.0% |
| Dec 18, 2026 | 51 | 54.8% | ±12.0% |
| Jan 15, 2027 | 79 | 43.3% | ±17.3% |
| Feb 19, 2027 | 114 | 48.7% | ±19.1% |
| May 21, 2027 | 205 | 39.4% | ±24.4% |
30-day implied volatility 47.1% vs 12.3% realized over the last 30 trading days. Put/call ratio (volume) 0.12. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 02:40 UTC)
| Price | USD 13.37 |
|---|---|
| Change | ▼ 1.55% (down) |
| Previous Close | USD 13.58 |
| Open | USD 13.52 |
| Day Range | USD 13.32 – 13.62 |
| 52-Week Range | USD 12.72 – 16.67 |
| Volume | 536,105 shares |
| Market Cap | $769.37M |
| Exchange | NMS |
Technical Analysis (INMD)
Nexqual's technical model rates INMD "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 02:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.47 (oversold) |
| vs SMA50 | Below (USD 14.44) |
| MACD | -0.21 (negative) |
Analyst Ratings (INMD)
Wall Street analysts rate INMD "Hold" based on 5 analysts, with a mean price target of USD 16.17 (range USD 15–17), per Nexqual as of October 29, 2026 at 02:40 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 16.17 |
| High Target | USD 17 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 0 / 5 / 0 |
Earnings (INMD)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD 0.32 |
| Revenue Estimate | $90.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.35 vs est 0.33 ▲ beat |
| 2026-03-31 | USD 0.25 vs est 0.3 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.42 ▲ beat |
| 2025-09-30 | USD 0.38 vs est 0.35 ▲ beat |
Source: Nexqual, October 29, 2026 at 02:40 UTC.
Financials & Fundamentals (INMD)
| Total Revenue | $374.62M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.00% |
| Gross Margin | +76.52% |
| Operating Margin | +12.82% |
| Profit Margin | +20.69% |
| ROE | +12.33% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.18 |
| Total Cash | $501.12M |
| Total Debt | $4.45M |
Source: Nexqual, October 29, 2026 at 02:40 UTC.
Financial Health Score (INMD)
Nexqual rates InMode Ltd.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 02:40 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 13% (last 12 months) |
| Balance Sheet | Strong — $501M cash vs $4M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $84M (TTM) |
| Efficiency | Mixed — ROE 12%, ROA 6.2% |
Ownership (INMD)
| Insider Ownership | +13.16% |
|---|---|
| Institutional Ownership | +55.51% |
| Shares Outstanding | 57.54M |
| Float | 49.12M |
| Short % of Float | +4.37% |
Source: Nexqual, October 29, 2026 at 02:40 UTC.
Leadership (INMD)
InMode Ltd. is led by Michael Kreindel, Co-Founder, CTO & Director, per Nexqual as of October 29, 2026 at 02:40 UTC.
| Co-Founder, CTO & Director | Michael Kreindel |
|---|
Major Backers & Investors (INMD)
Notable institutional backers of InMode Ltd. include Doma Perpetual Capital Management LLC, Acadian Asset Management. LLC, Renaissance Technologies, according to Nexqual as of October 29, 2026 at 02:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Doma Perpetual Capital Management LLC | 4.75% |
| Acadian Asset Management. LLC | 4.5% |
| Renaissance Technologies | 4.16% |
| Menora Mivtachim Holdings Ltd. | 3.55% |
| Steel Partners Holdings, LP | 3.18% |
| Millennium Management | 3.05% |
| Morgan Stanley | 1.94% |
| Systematic Financial Management, L.P. | 1.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.34% |
Source: Nexqual, October 29, 2026 at 02:40 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 02:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt